Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00186875Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Nov 2003
- Primary completion
- Aug 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide and teniposide in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Response Rate at 1 month and Overall Survival at 4 years. Started Nov 2003; status: completed.
02
Drugs
etoposideteniposide
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00186875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00186875.